Abstract illustration symbolizing the complexity of PCOS diagnosis.

PCOS Overdiagnosis? Why More Women Are Being Mislabelled

"Are expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome? Experts raise concerns about overdiagnosis and the potential harms of labeling women, particularly younger women and those with milder symptoms."


Polycystic Ovary Syndrome (PCOS) stands as the most frequently diagnosed endocrine disorder among women of reproductive age, impacting fertility, reproductive health, metabolic function, cardiovascular health, and psychosocial well-being. Characterized by symptoms such as anovulation, irregular menstruation, ovaries appearing polycystic, and signs of androgen excess, PCOS manifests diversely, influenced by weight, ethnicity, and environmental factors. The severity of these symptoms varies significantly among individuals.

Over the years, the diagnostic criteria for PCOS have broadened, leading to an increase in the number of women diagnosed. This expansion has sparked concerns about potential overdiagnosis and unnecessary disease labeling, prompting a critical examination of the evidence and uncertainties surrounding PCOS diagnosis.

Originally identified in 1935 through a case series of seven women experiencing amenorrhea and infertility linked to multiple ovarian cysts, the diagnostic landscape of PCOS has evolved. Today, three distinct diagnostic criteria are in use, each contributing to the ongoing debate about who should be diagnosed with PCOS and what the implications are for their health.

AI Search Multiple angles on this topic

Prevalence Figures and Hidden Case Counts

The WHO estimates that PCOS affects 10-13% of reproductive-aged women, and that up to 70% of women with the condition worldwide do not know they have it. The WHO also identifies PCOS as the most common cause of anovulation among women globally and a leading cause of infertility. Some statistics aggregators additionally report that PCOS is linked to a roughly threefold higher risk of cardiovascular disease, including hypertension and atherosclerosis, although at least one such source flags this figure as provisional, noting it rests on a single traceable line of evidence.

Stepped Care and Failing Tracking Tools

Standard management of PCOS typically follows a stepped approach that begins with conservative methods before moving to more advanced options. Yet the standard tools women rely on to track the condition often come up short: ovulation apps and OPK test strips frequently fail in PCOS because of high baseline LH and irregular cycles, which is why some sources recommend multi-signal tracking combining OPK, basal body temperature, and PdG. The standard picture also varies by patient - lean PCOS, for instance, describes the condition in women whose BMI is within normal limits, and for that group the nutritional goal is not weight loss, a distinction that separates it from the ordinary PCOS approach.

Recognized for Decades, Yet Still Missed

PCOS has long been recognized as a common hormonal disorder affecting how the ovaries function, with estimates that it impacts up to 1 in 10 women of reproductive age while around 70% of cases remain undiagnosed. A recurring theme in the disorder's history is that its core symptoms - weight gain, irregular periods, acne, and anxiety - are frequently attributed to other causes, delaying recognition. Awareness has since broadened across the lifespan: adolescent care now emphasizes catching early signs such as irregular periods and weight gain in teenagers, while other accounts track how PCOS symptoms shift as women approach menopause.

The Shifting Sands of Diagnosis

Abstract illustration symbolizing the complexity of PCOS diagnosis.

The National Institutes of Health (NIH) established the first widely used diagnostic criteria in 1990. These criteria focused on the presence of both oligo-ovulation (irregular or infrequent ovulation) or anovulation (absence of ovulation) and clinical or biochemical signs of hyperandrogenism (excess androgens, male hormones).

A significant shift occurred in 2003 during a meeting of experts in Rotterdam. The Rotterdam criteria expanded the diagnostic net by including the sonographic presence of polycystic ovaries as one of the diagnostic features. Under these revised criteria, a woman needed only two out of the three characteristics—oligo- or anovulation, hyperandrogenism, or polycystic ovaries—to be diagnosed with PCOS. This broadened the scope of diagnosis considerably.

  • NIH Criteria (1990): Requires both oligo/anovulation and hyperandrogenism.
  • Rotterdam Criteria (2003): Requires two out of three: oligo/anovulation, hyperandrogenism, or polycystic ovaries.
  • AE-PCOS Society Criteria (2006): Requires hyperandrogenism and either oligo/anovulation or polycystic ovaries.
AI Search Multiple angles on this topic

Moving From Symptoms Toward Personalization

Reviews of PCOS commonly frame the condition around its core features - irregular cycles, excess bodily hair growth, weight gain, and complications with fertility - while recent research summaries emphasize that presentation varies widely between individuals. Current literature updates accordingly stress personalized treatment options aimed at controlling and managing the condition, with some sources suggesting it may be possible to potentially reverse aspects of it. Aggregators of recent PCOS research note that accessible, verified summaries of new studies are helping patients understand what each finding means for them.

When First-Line Treatment Stumbles

Lifestyle interventions are considered first-line treatment for PCOS, which affects up to 13% of women, yet adherence is a major failure point: attrition among women with PCOS is high, undermining a cornerstone of care. Counter-narratives to standard advice also argue that PCOS is not a one-size-fits-all diagnosis, and that recognizing an individual's specific symptom profile and pursuing tailored strategies is essential to more effective management and improved health outcomes.

PCOS Alongside PCOD and Endometriosis

PCOS is frequently compared with related reproductive conditions, and distinctions are often drawn along diagnostic lines: PCOD is characterized as a functional disorder, whereas PCOS is considered an endocrine-metabolic syndrome. Hospital comparison tables lay out the differences between PCOD and PCOS across symptoms, hormonal profiles, and treatment approach. PCOS also overlaps with other reproductive conditions such as endometriosis - both affect the reproductive system, share some symptoms, and can cause heavy bleeding and difficulty getting pregnant.

The Androgen Excess and PCOS Society in 2006 stipulated that clinical or biochemical evidence of hyperandrogenism was essential for a PCOS diagnosis. This perspective highlighted the importance of androgen excess in the syndrome's pathology, suggesting that non-hyperandrogenic phenotypes might not carry the same long-term health risks as hyperandrogenic ones. Despite these evolving perspectives, in 2012, an NIH workshop reviewed available evidence and recommended maintaining the broader Rotterdam criteria, while also suggesting the labeling of PCOS phenotypes to better characterize the syndrome's heterogeneity.

Navigating the Uncertainties

Given the evolving understanding of PCOS and the potential for overdiagnosis, a more cautious and individualized approach to diagnosis is warranted. Rather than applying a one-size-fits-all label, healthcare providers should carefully weigh the benefits and harms for each woman, considering her individual symptoms, risk factors, and preferences. A slower, stepped, or delayed approach to diagnosis may be more appropriate, allowing for ongoing monitoring and evaluation before committing to a lifelong label.

AI Search Multiple angles on this topic

Cautious Experts on Cure and Diagnosis

Expert commentary is notably cautious about the permanence of treatment: specialists say a hysterectomy is not a reliable fix for PCOS, and even when the ovaries are preserved, symptoms can keep coming back. On the diagnostic side, experts highlight persistent challenges in identifying PCOS, particularly in adolescents, and point to an unmet need for an accurate serum test that could enable earlier diagnosis in teenage girls. At the same time, broad clinical overviews describe PCOS as a hormonal disorder that disrupts menstruation, while fertility-focused experts weigh success rates and treatment options for those trying to conceive.

Microbes, Metabolic Pathways, and New Drugs

The gut microbiome is emerging as a new frontier in PCOS research, with scientists investigating whether modulating gut microbiota could become a treatment strategy for the condition. In one study, researchers tested a probiotic strain of Akkermansia muciniphila in rats, targeting gut microbiota and metabolic pathways as a possible therapeutic approach for managing PCOS. Separately, research into semaglutide for PCOS is expected to examine its long-term effects and optimal dosing, including combining it with other treatments.

Diagnostic Turmoil and Systemic Burden

A major systemic challenge is diagnosis itself: reviews note that the diagnostic criteria for PCOS have been challenged across all three pillars and have evolved repeatedly over time. Compounding that, PCOS is described as a complex metabolic condition affecting multiple body systems, which makes it challenging to treat. The relationship with obesity illustrates a vicious cycle - obesity exacerbates PCOS symptoms while PCOS complicates weight loss - and US-focused analyses point to the compounding burden the condition places on women's long-term health, the healthcare system, and the national economy.

Individual Case Studies and Long-Term Cognitive Concerns

Real-world case studies illustrate the highly individual nature of PCOS: one clinic's report on metformin treatment documented an 82.8% boost in menstrual regularity and a 34% drop in testosterone among participants, alongside broader metabolic improvements and hormonal regulation. Clinicians also use case studies like a DUTCH test review of a patient in her 20s to demonstrate how PCOS-like symptoms can be differentiated from other conditions. Longer term, research following women into middle age has linked PCOS to memory and thinking concerns, with one MRI sub-study of 291 participants (25 of whom had PCOS) finding lower white matter integrity.

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1136/bmj.j3694, Alternate LINK

Title: Are Expanding Disease Definitions Unnecessarily Labelling Women With Polycystic Ovary Syndrome?

Subject: General Engineering

Journal: BMJ

Publisher: BMJ

Authors: Tessa Copp, Jesse Jansen, Jenny Doust, Ben Wj Mol, Anuja Dokras, Kirsten Mccaffery

Published: 2017-08-16

Everything You Need To Know

1

What are the different diagnostic criteria used for Polycystic Ovary Syndrome (PCOS), and how have they evolved?

Polycystic Ovary Syndrome (PCOS) is diagnosed based on specific criteria, which have evolved over time. The original NIH criteria (1990) required both oligo/anovulation and hyperandrogenism. The Rotterdam criteria (2003) broadened this to include two out of three characteristics: oligo/anovulation, hyperandrogenism, or polycystic ovaries. The AE-PCOS Society criteria (2006) emphasized hyperandrogenism as essential, along with either oligo/anovulation or polycystic ovaries. This evolution reflects ongoing debates about the syndrome's defining features.

2

How did the Rotterdam criteria change the landscape of PCOS diagnosis, and why is this significant?

The Rotterdam criteria, established in 2003, significantly broadened the scope of PCOS diagnosis. These criteria state that a woman needs only two out of the three characteristics—oligo- or anovulation, hyperandrogenism, or polycystic ovaries—to be diagnosed with PCOS. This expansion has led to concerns about potential overdiagnosis, as the inclusion of polycystic ovaries alone, without other symptoms, can result in more women being labeled with the syndrome.

3

In what specific way do the AE-PCOS Society criteria differ from the Rotterdam criteria in diagnosing Polycystic Ovary Syndrome (PCOS)?

The AE-PCOS Society criteria, established in 2006, differ by requiring clinical or biochemical evidence of hyperandrogenism as essential for a PCOS diagnosis. Unlike the Rotterdam criteria, which allow a diagnosis based on two out of three criteria (including polycystic ovaries alone), the AE-PCOS Society emphasizes the importance of androgen excess in the syndrome's pathology. This perspective suggests that non-hyperandrogenic phenotypes might not carry the same long-term health risks as hyperandrogenic ones, leading to a more targeted diagnosis approach.

4

What are the potential harms and risks associated with the overdiagnosis of Polycystic Ovary Syndrome (PCOS) for women's health?

Overdiagnosis of Polycystic Ovary Syndrome (PCOS) carries several risks. It can lead to unnecessary medical interventions, increased anxiety and psychological distress related to the diagnosis. Additionally, labeling women, especially younger women and those with milder symptoms, may result in unwarranted long-term health concerns and impact their reproductive and metabolic well-being unnecessarily. It also strains healthcare resources and potentially diverts attention from women who genuinely need treatment.

5

Given the uncertainties in PCOS diagnosis, what approach should healthcare providers adopt to ensure accurate diagnosis and minimize potential harms?

Navigating the uncertainties of PCOS diagnosis involves a more cautious and individualized approach. Healthcare providers should carefully weigh the benefits and potential harms for each woman, considering her individual symptoms, risk factors, and preferences. This approach might involve a slower, stepped, or delayed diagnosis, allowing for ongoing monitoring and evaluation before assigning a lifelong label. A comprehensive assessment ensures that the diagnosis aligns with the woman's overall health profile and reduces the risk of overdiagnosis and its associated harms. Further research is needed to refine diagnostic criteria and understand the long-term implications of different PCOS phenotypes.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.